A woman who underwent dilatation and curettage for molar pregnancy 6 months ago presents with persistent symptoms of abdominal pain and distention. On further evaluation, the beta – hCG levels were persistently elevated and cannonball foci were found on the chest X-ray. What is the appropriate management in this case?

Explanation

## Correct Answer: B. Methotrexate with folinic acid This patient has persistent gestational trophoblastic disease (GTD) with pulmonary metastases, evidenced by elevated β-hCG 6 months post-evacuation and cannonball opacities on chest X-ray. The cannonball pattern is pathognomonic for metastatic GTD to lungs. According to FIGO scoring and Indian guidelines (RNTCP/NTEP protocols adapted for GTD), this represents **low-risk metastatic disease** (β-hCG <40,000 IU/L, no brain/liver metastases, and >4 months from antecedent pregnancy). Low-risk metastatic GTD is managed with **single-agent chemotherapy**, specifically methotrexate. However, methotrexate is a folate antagonist that causes severe myelosuppression and mucositis. **Folinic acid (leucovorin) rescue** is mandatory—it bypasses the DHFR block and rescues normal cells while allowing continued tumor cell death. The standard regimen is methotrexate 1 mg/kg IV/IM on days 1, 3, 5, 7 followed by folinic acid 0.1 mg/kg on days 2, 4, 6, 8 (8-day cycle). This combination prevents life-threatening toxicity while maintaining efficacy. Methotrexate monotherapy without folinic acid would cause unacceptable toxicity and is not standard practice in Indian oncology centers. ## Why the other options are wrong **A. EMACO regimen** — EMACO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) is reserved for **high-risk metastatic GTD** (β-hCG >40,000 IU/L, brain/liver metastases, or <4 months from antecedent event). This patient has low-risk disease with β-hCG likely <40,000 and >4 months post-evacuation. Over-treatment with EMACO causes unnecessary toxicity and is not indicated per FIGO criteria. **C. Hysterectomy** — Hysterectomy is considered only in **chemotherapy-resistant disease** or when fertility is not desired and there is persistent uterine GTD despite chemotherapy. Primary management of metastatic GTD is always chemotherapy first, not surgery. Hysterectomy alone without chemotherapy will not eliminate metastatic foci in the lungs and is inappropriate as first-line therapy. **D. Methotrexate** — Methotrexate monotherapy without folinic acid rescue is **contraindicated** due to severe toxicity (myelosuppression, mucositis, renal damage). Folinic acid rescue is not optional—it is a mandatory component of the regimen. Giving methotrexate alone would cause life-threatening complications and violates standard Indian oncology practice guidelines. ## High-Yield Facts - **Cannonball opacities** on CXR are pathognomonic for metastatic GTD to lungs and indicate need for systemic chemotherapy. - **FIGO risk stratification**: low-risk metastatic GTD (β-hCG <40,000, no brain/liver mets, >4 months from antecedent) → single-agent methotrexate; high-risk → EMACO. - **Folinic acid rescue** is mandatory with methotrexate to prevent fatal toxicity by bypassing DHFR blockade in normal cells while preserving tumor cell death. - **Methotrexate dosing** in GTD: 1 mg/kg IV/IM days 1, 3, 5, 7; folinic acid 0.1 mg/kg days 2, 4, 6, 8 (8-day cycle). - **Persistent GTD** after molar pregnancy evacuation requires β-hCG monitoring; elevation >5 IU/L at 3 weeks or any rise after initial decline indicates need for chemotherapy. ## Mnemonics **GTD Risk Stratification (FIGO)** **LOW-RISK**: β-hCG <40K, no brain/liver mets, >4 months from antecedent → MTX monotherapy. **HIGH-RISK**: β-hCG >40K, brain/liver mets, <4 months → EMACO. Use this to pick single-agent vs. multi-agent chemotherapy. **MTX + Folinic Acid (Rescue Rule)** MTX blocks folate → folinic acid RESCUES normal cells. Never give MTX without folinic acid in GTD. Memory: **MTX kills, folinic acid saves**—both are essential. ## NBE Trap NBE may pair "methotrexate" alone (option D) to trap students who know MTX is used in GTD but forget that **folinic acid rescue is mandatory**—a common oversight in Indian medical education where the rescue component is sometimes underemphasized relative to the drug itself. ## Clinical Pearl In Indian tertiary centers, persistent GTD with pulmonary metastases is increasingly common due to delayed diagnosis in resource-limited settings. Early recognition of cannonball opacities and prompt chemotherapy initiation with folinic acid rescue prevents progression to high-risk disease and preserves fertility in young women—a critical outcome in Indian obstetric practice. _Reference: DC Dutta's Textbook of Obstetrics (3rd ed.), Ch. 24 (Gestational Trophoblastic Disease); FIGO Scoring System for GTD (2000, adapted in Indian guidelines)_